|This article does not cite any references or sources. (June 2009)|
|Jmol-3D images||Image 1|
|Molar mass||451.37 g/mol|
| (what is: / ?)
Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
Capravirine was a non-nucleoside reverse transcriptase inhibitor which reached phase II trials before development was discontinued by Pfizer. Both phase IIb trials which were conducted failed to demonstrate that therapy with capravirine provided any significant advantage over existing triple-drug HIV therapies, and pharmacology studies showed that capravirine may interact with other HIV drugs.
|This antiinfective drug article is a stub. You can help Wikipedia by expanding it.|